BSE Live
Nov 07, 16:01Prev. Close
192.25
Open Price
192.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 07, 15:53Prev. Close
192.83
Open Price
192.83
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
189.68 (636)
| Key Financial Ratios of Suven Life Sciences (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 9.04 | 12.34 | 2.64 | 1.23 | 0.89 | |
| Diluted EPS (Rs.) | 9.04 | 12.34 | 2.64 | 1.23 | 0.89 | |
| Cash EPS (Rs.) | 9.47 | 13.10 | 3.31 | 1.74 | 1.36 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 43.94 | 22.64 | 13.22 | 10.92 | 10.86 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 43.94 | 22.64 | 13.22 | 10.92 | 10.86 | |
| Dividend / Share(Rs.) | 0.60 | 2.50 | 0.30 | 0.30 | 0.25 | |
| Revenue from Operations/Share (Rs.) | 40.92 | 43.68 | 22.07 | 17.49 | 12.89 | |
| PBDIT/Share (Rs.) | 13.20 | 19.01 | 4.64 | 2.15 | 1.27 | |
| PBIT/Share (Rs.) | 12.28 | 18.25 | 3.97 | 1.63 | 0.80 | |
| PBT/Share (Rs.) | 11.91 | 17.35 | 2.81 | 0.78 | 0.28 | |
| Net Profit/Share (Rs.) | 8.54 | 12.34 | 2.64 | 1.23 | 0.89 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 32.26 | 43.52 | 21.02 | 12.26 | 9.84 | |
| PBIT Margin (%) | 30.00 | 41.78 | 17.97 | 9.32 | 6.22 | |
| PBT Margin (%) | 29.09 | 39.72 | 12.73 | 4.47 | 2.16 | |
| Net Profit Margin (%) | 20.87 | 28.24 | 11.95 | 7.03 | 6.91 | |
| Return on Networth / Equity (%) | 19.44 | 54.51 | 19.96 | 11.26 | 8.20 | |
| Return on Capital Employed (%) | 16.84 | 43.47 | 14.00 | 7.79 | 6.39 | |
| Return on Assets (%) | 14.06 | 29.62 | 9.22 | 5.03 | 4.65 | |
| Total Debt/Equity (X) | 0.16 | 0.25 | 0.60 | 0.61 | 0.46 | |
| Asset Turnover Ratio (%) | 67.36 | 104.86 | 77.18 | 71.65 | 67.26 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.74 | 1.82 | 1.26 | 1.04 | 1.55 | |
| Quick Ratio (X) | 3.10 | 1.31 | 0.79 | 0.58 | 1.00 | |
| Inventory Turnover Ratio (X) | 6.37 | 6.49 | 4.79 | 4.39 | 4.51 | |
| Dividend Payout Ratio (NP) (%) | 7.02 | 20.26 | 11.36 | 24.38 | 28.06 | |
| Dividend Payout Ratio (CP) (%) | 6.33 | 19.09 | 9.05 | 17.20 | 18.41 | |
| Earnings Retention Ratio (%) | 92.98 | 79.74 | 88.64 | 75.62 | 71.94 | |
| Cash Earnings Retention Ratio (%) | 93.67 | 80.91 | 90.95 | 82.80 | 81.59 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 3,479.56 | 836.88 | 337.76 | 235.92 | 250.04 | |
| EV/Net Operating Revenue (X) | 6.68 | 1.64 | 1.31 | 1.16 | 1.66 | |
| EV/EBITDA (X) | 20.71 | 3.77 | 6.23 | 9.42 | 16.89 | |
| MarketCap/Net Operating Revenue (X) | 7.05 | 1.65 | 1.04 | 0.79 | 1.29 | |
| Retention Ratios (%) | 92.97 | 79.73 | 88.63 | 75.61 | 71.93 | |
| Price/BV (X) | 6.56 | 3.18 | 1.73 | 1.26 | 1.53 | |
| Price/Net Operating Revenue | 7.05 | 1.65 | 1.04 | 0.79 | 1.29 | |
| Earnings Yield | 0.03 | 0.17 | 0.12 | 0.09 | 0.05 |
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
08.01.2025
Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
30.10.2024
Suven Life Sci Consolidated September 2024 Net Sales at Rs 2.57 crore, down 15.91% Y-o-Y